The latest research of Baylor Institute and Charles & salmon Cancer Center shows that the antidepressant effect of bcm-95 curcumin supplement is similar to that of prescription drug fluoxetine for major depressive disorder (MDD), and there is no adverse reaction.
In this study, researchers recruited 20 patients diagnosed with MDD and randomly divided them into three groups. One group used 500mg of bcm-95 curcumin twice a day; The other group received 20 mg fluoxetine once a day; Another group used curcumin twice in combination with fluoxetine once. The severity of depression was assessed by emotion, insomnia, agitation, guilt, suicidal thinking, suicide or anxiety, muscle delay, weight loss, and other physical symptoms. The study lasted six weeks.
The results showed that all participants had good curcumin tolerance. The combination group had the best recovery index, reaching 77.8%, the pure curcumin group was 65.2%, and the fluoxetine group was 64.7%, but there was no significant difference between these data. The effect of bcm-95 curcumin is similar to that of fluoxetine. This study confirms the clinical application effect of curcumin on MDD patients for the first time.
